How Mabion's Polish CDMO Offers Cost-Effective Solutions for North American Biotechs

Update: 2024-10-17

Description

"As Americans, we are very unaware of the value proposition of Poland," says Marty Henehan, highlighting the untapped potential of Central European biopharmaceutical manufacturing for North American biotechs.

Marty Henehan, Vice President of Business Development and Head of North America at Mabion sheds light on the advantages of partnering with a Polish CDMO for drug development and manufacturing services.

Speaking to the PharmaSource podcast during CPHI Milan, Marty explains how Mabion's transformation from a biosimilar company to a full-service CDMO has positioned them to offer cost-effective, high-quality solutions for biotechs worldwide, particularly those in North America.

Read the full article

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

From Platform to Product Development: Integra Therapeutics’ CEO on Scaling Gene Editing

2024-11-1820:54

ADC Manufacturing: Are only 5 CDMOs fit for purpose?

2024-11-1337:16

GLP 1s and the Unintended Consequences of the $100 Billion Market

2024-11-0732:50

Virtual Plant Best Practices: Interview with Federica Fraschetti, MSD

2024-10-2838:18

How Sharp is Driving Sustainability in Pharmaceutical Packaging and Clinical Services

2024-10-2314:40

How Bristol Myers Squibb Optimises Its Global Manufacturing Network Strategy – Interview with Daniel Hurni

2024-10-2241:58

The CPHI Podcast: Conversations from the show floor at CPHI Milan with Recipharm, Tjoapack, Renaissance Lakewood, Ecolab and NovaCina

2024-10-2037:15

How Mabion's Polish CDMO Offers Cost-Effective Solutions for North American Biotechs

2024-10-1709:41

SK pharmteco CEO, Joerg Ahlgrimm: Multi-Modality Growth Strategy in a Consolidating CDMO Landscape

2024-10-1620:14

How Acino Manages 90 CMOs Across Emerging Markets: A Masterclass in Supply Chain Resilience

2024-10-1508:44

CordenPharma’s €900M Expansion: Racing to Meet Soaring GLP-1 Demand

2024-10-1515:24

Thermo Fisher’s Accelerator™ Drug Development Platform Explained: Interview with Dr. Anil Kane

2024-10-1510:15

Adragos Pharma's Mission to Reshape Contract Manufacturing: Interview with Henny Zijlstra, Chief Commercial Officer

2024-10-1409:01

Cell Therapy Manufacturing Partnerships: Interview with Sonoma Biotherapeutics’ Jessica Brantley

2024-10-0321:17

Key Lessons in CDMO Selection from Firelli Alonso

2024-09-2733:26

How Camida Tackles Pharmaceutical Raw Material Sourcing in a Changing Global Landscape

2024-09-2329:35

How Cell and Gene Therapy can overcome the ‘Hubris of Science’ – Accenture’s Sanjay Srivastava

2024-09-2037:42

Quality Oversight Plans: Key Strategies for Effective Oversight in Pharma Manufacturing with Stephanie Gaulding

2024-09-1650:41

How Bioeq Mastered the Virtual Manufacturing Model

2024-09-0927:50

How Teva Pharmaceuticals Became a Global Leader in Sustainability

2024-08-2330:54

00:00

How Mabion's Polish CDMO Offers Cost-Effective Solutions for North American Biotechs

#box-pro-ellipsis-17322447771977{-webkit-line-clamp:2;}How Mabion's Polish CDMO Offers Cost-Effective Solutions for North American Biotechs

How Mabion's Polish CDMO Offers Cost-Effective Solutions for North American Biotechs

Life Science Networks

How Mabion's Polish CDMO Offers Cost-Effective Solutions for North American Biotechs